Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Public ClinicalTrials.gov record NCT03226392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent (≥ 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second (FEV1) at the end of 12 weeks of treatment.
Study identification
- NCT ID
- NCT03226392
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 704 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2017 (Actual)
- Primary completion
- Jul 5, 2019 (Actual)
- Completion
- Aug 1, 2019 (Actual)
- Last update posted
- Jan 13, 2026
2017 – 2019
United States locations
- U.S. sites
- 45
- U.S. states
- 22
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Andalusia | Alabama | 36420 | — |
| Novartis Investigative Site | Birmingham | Alabama | 35209 | — |
| Novartis Investigative Site | Tucson | Arizona | 85745 | — |
| Novartis Investigative Site | Los Angeles | California | 90048 | — |
| Novartis Investigative Site | Newport Beach | California | 92663 | — |
| Novartis Investigative Site | Rolling Hills Estates | California | 90274 | — |
| Novartis Investigative Site | San Diego | California | 92117 | — |
| Novartis Investigative Site | San Diego | California | 92120 | — |
| Novartis Investigative Site | San Jose | California | 95117 | — |
| Novartis Investigative Site | Stockton | California | 95207 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80907 | — |
| Novartis Investigative Site | Denver | Colorado | 80230 | — |
| Novartis Investigative Site | Lafayette | Colorado | 80026 | — |
| Novartis Investigative Site | Miami | Florida | 33176 | — |
| Novartis Investigative Site | Miami Gardens | Florida | 33169 | — |
| Novartis Investigative Site | Tallahassee | Florida | 32308 | — |
| Novartis Investigative Site | Winter Park | Florida | 32789 | — |
| Novartis Investigative Site | Paducah | Kentucky | 42001 | — |
| Novartis Investigative Site | Columbia | Maryland | 21044 | — |
| Novartis Investigative Site | White Marsh | Maryland | 21162 | — |
| Novartis Investigative Site | North Dartmouth | Massachusetts | 02747-3322 | — |
| Novartis Investigative Site | Ann Arbor | Michigan | 48106 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55402 | — |
| Novartis Investigative Site | Rochester | Minnesota | 55905 | — |
| Novartis Investigative Site | Saint Charles | Missouri | 63301 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | St Louis | Missouri | 63141 | — |
| Novartis Investigative Site | Warrensburg | Missouri | 64093 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68134 | — |
| Novartis Investigative Site | Brooklyn | New York | 11235 | — |
| Novartis Investigative Site | Raleigh | North Carolina | 27607 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45245 | — |
| Novartis Investigative Site | Columbus | Ohio | 43215 | — |
| Novartis Investigative Site | Marion | Ohio | 43302 | — |
| Novartis Investigative Site | Mayfield Heights | Ohio | 44124 | — |
| Novartis Investigative Site | Tulsa | Oklahoma | 74136 | — |
| Novartis Investigative Site | Altoona | Pennsylvania | 16602 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15241 | — |
| Novartis Investigative Site | Mt. Pleasant | South Carolina | 29464 | — |
| Novartis Investigative Site | Dallas | Texas | 75231 | — |
| Novartis Investigative Site | New Braunfels | Texas | 78130 | — |
| Novartis Investigative Site | San Antonio | Texas | 78205 | — |
| Novartis Investigative Site | Murray | Utah | 84107 | — |
| Novartis Investigative Site | Newport News | Virginia | 23606 | — |
| Novartis Investigative Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03226392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03226392 live on ClinicalTrials.gov.